Status:
COMPLETED
Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma
Lead Sponsor:
Institut Claudius Regaud
Collaborating Sponsors:
AstraZeneca
Conditions:
Diffuse Large B-cell Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This trial is a translational, prospective, open-label, monocentric research. The study will be conducted in a population of 60 patients with diffuse large B-cell lymphoma (DLBCL) for whom first-line...
Eligibility Criteria
Inclusion
- Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP (treatment by R-CHOP should not have been initiated prior to inclusion in the study)
- Age 18 to 80 years at the time of study entry
- Archived initial diagnostic tumor specimen available
- Life expectancy ≥ 3months
- ECOG Performance status 0-2
- FDG-avid disease (for PET monitoring)
- Signed written informed consent
- Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol
- Patient affiliated to a Social Health Insurance in France
Exclusion
- Patient pregnant, or breast-feeding
- Any condition contraindicated with tumor / blood sampling procedures required by the protocol
- Central Nervous System (CNS) involvement
- Known history of positive test for Hepatitis B virus or Hepatitis C virus or Immunodeficiency Virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Any current severe or uncontrolled disease, including, but not limited to ongoing or active infection and auto immune disorders
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
- Current participation in any other therapeutic clinical study
Key Trial Info
Start Date :
February 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 11 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04696692
Start Date
February 9 2021
End Date
December 11 2025
Last Update
December 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, France, 31059